GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

计划入组 160 人 · 首次发布于 2023 年 1 月 25 日

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

计划入组 1,594 人 · 首次发布于 2022 年 2 月 17 日

GLP-1 RA for Stage 1 Type 1 Diabetes

计划入组 15 人 · 首次发布于 2026 年 2 月 24 日

1-naphthaleneacetic acid

C₁₂H₁₀O₂

HH-1-1

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Teclistamab Shows Sustained Efficacy in Relapsed/Refractory Multiple Myeloma

Teclistamab Shows Promise in Heavily Pretreated Multiple Myeloma

NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma